Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
COLBENEMID vs CHOLAC
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Colchicine inhibits microtubule polymerization, reducing neutrophil chemotaxis and inflammation. Probenecid inhibits renal tubular reabsorption of uric acid, increasing uric acid excretion.
Lactulose is a synthetic disaccharide that is not absorbed in the small intestine. It is metabolized by colonic bacteria to short-chain fatty acids, primarily lactic acid and acetic acid, which lower the colonic p H. This acidification traps ammonia (NH3) as ammonium (NH4+) in the gut lumen, reducing serum ammonia levels. Additionally, the osmotic effect of lactulose draws water into the colon, producing a laxative effect.
Prophylaxis and treatment of acute gout flares,Hyperuricemia associated with gout (probenecid component)
Treatment of hepatic encephalopathy (portal-systemic encephalopathy) in patients with acute and chronic liver disease,Constipation (including chronic idiopathic constipation)
Adults: 1 tablet (probenecid 500 mg / colchicine 0.5 mg) orally once daily for first week, then twice daily thereafter. May increase to 3-4 tablets daily in divided doses if needed.
15-30 m L (10-20 g lactulose) orally once daily, titrated to produce 2-3 soft stools per day; maximum dose 60 m L/day. For hepatic encephalopathy: 30-45 m L (20-30 g) orally 3-4 times daily, titrated to 2-3 soft stools per day.
Probenecid: 6-12 hours (dose-dependent); colchicine: 20-30 hours (terminal) in renal impairment may prolong.
0.5-1.5 hours for lactulose; active metabolites (e.g., acetic acid) have negligible systemic half-life due to rapid local metabolism.
Colchicine: primarily hepatic via CYP3A4; Probenecid: hepatic metabolism via glucuronidation and oxidation.
Not absorbed systemically. Metabolized by colonic bacteria (e.g., Lactobacillus, Bacteroides) to lactic acid, acetic acid, and other short-chain fatty acids.
Renal: ~76% as unchanged probenecid and metabolites; biliary/fecal: minor (<5%). Colchicine: ~20% renal, ~80% fecal primarily via biliary excretion.
Primarily fecal (biliary excretion of unchanged drug and metabolites); minimal renal excretion (<5%).
Probenecid: ~85-95% primarily to albumin; colchicine: ~30-50% to albumin and other proteins.
Negligible (<1%); not significantly bound to plasma proteins.
Probenecid: 0.15-0.2 L/kg (confined to plasma and extracellular fluid); colchicine: 2-8 L/kg (wide tissue distribution, high in leukocytes).
Approximately 0.2 L/kg; indicates distribution primarily in extracellular fluid.
Probenecid: ~100% oral; colchicine: ~45% oral (range 25-50%) with significant first-pass metabolism.
Oral: <2% systemic bioavailability due to extensive first-pass metabolism and local gut action; rectal: minimal systemic absorption.
Cr Cl <50 m L/min: contraindicated. Cr Cl 50-80 m L/min: reduce dose by 50% or extend interval. Cr Cl >80 m L/min: no adjustment.
No dose adjustment required for renal impairment.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50% or use with caution. Child-Pugh C: contraindicated (risk of colchicine accumulation).
No specific Child-Pugh based adjustments. Use with caution in severe hepatic impairment due to risk of electrolyte disturbances; monitor serum electrolytes.
Not recommended for pediatric use; safety and efficacy not established.
Infants: 2.5-10 m L/day in divided doses. Children: 40-90 mg/kg/day (as lactulose) divided 1-2 times daily, titrated to produce soft stools. For hepatic encephalopathy: 2.5-10 m L (1.7-6.7 g) orally 3-4 times daily, titrated to 2-3 soft stools per day.
Start at lowest dose (e.g., 1 tablet daily) and titrate slowly; monitor renal function and avoid in Cr Cl <50 m L/min. Consider reduced doses due to increased risk of toxicity.
Initiate at lower end of dosing range (15 m L once daily) and titrate slowly to avoid diarrhea and electrolyte imbalance; monitor renal function and electrolytes.
No FDA boxed warning.
No FDA black box warning.
Severe toxicity with colchicine in renal/hepatic impairment; blood dyscrasias (probenecid); increased risk of colchicine toxicity with CYP3A4 inhibitors; avoid use with NSAIDs due to increased GI toxicity.
Electrolyte disturbances (e.g., hypernatremia) may occur, especially with prolonged use or in patients with renal impairment,Diarrhea can lead to fluid and electrolyte loss; dosage should be adjusted to produce 2-3 soft stools per day,Galactose content: lactulose contains galactose and lactose; use with caution in patients with galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption,Risk of colonic perforation in patients with severe colonic ulceration, toxic megacolon, or gastrointestinal obstruction
Hypersensitivity to colchicine or probenecid; severe renal impairment (Cr Cl < 30 m L/min); concurrent use of P-glycoprotein or strong CYP3A4 inhibitors (e.g., clarithromycin, ketoconazole) with colchicine; blood dyscrasias; peptic ulcer disease; acute gout flare treatment with history of uric acid renal calculi.
Patients with galactosemia (due to galactose content),Gastrointestinal obstruction (including ileus),Hypersensitivity to lactulose or any component of the formulation
Alcohol reduces efficacy and increases hyperuricemia; avoid completely. High-purine foods (e.g., red meat, organ meats, sardines, mussels) may exacerbate gout. Grapefruit juice may increase colchicine toxicity via CYP3A4 inhibition. Acidic foods (e.g., cranberries, prunes) can decrease urine p H and increase uric acid crystallization risk. Maintain adequate hydration with water.
No specific food restrictions. Mixing with fruit juice, water, or milk may improve taste. Avoid excessive intake of dairy products if lactose intolerant (lactulose may contain small amounts of lactose).
Colbenemid is a combination of colchicine and probenecid. Colchicine is associated with increased risk of fetal harm when administered during pregnancy, including chromosomal abnormalities and fetal death, particularly in the first trimester. Probenecid should be avoided in pregnancy due to potential teratogenic effects and neonatal toxicity. Overall, use is contraindicated in pregnant women.
Lactulose is not absorbed systemically; no teratogenic effects reported in animal studies or human case reports. FDA Pregnancy Category B. Trimester-specific risks: no known fetal harm in any trimester.
Colchicine is excreted into human milk with a milk-to-plasma ratio (M/P ratio) of approximately 0.9. Probenecid passes into breast milk in small amounts. Due to potential serious adverse effects in nursing infants, including gastrointestinal toxicity and bone marrow suppression, breastfeeding is not recommended during therapy.
Excretion into breast milk is negligible due to minimal systemic absorption. M/P ratio not determined. Considered compatible with breastfeeding.
No specific dose adjustment guidelines exist due to contraindication during pregnancy. Pharmacokinetic changes in pregnancy (e.g., increased renal clearance) may reduce efficacy, but use is not recommended.
No dose adjustment required during pregnancy; pharmacokinetics unchanged due to localized GI action.
Colbenemid is a fixed-dose combination of colchicine (0.5 mg) and probenecid (500 mg). Probenecid increases uric acid excretion by inhibiting renal tubular reabsorption; colchicine reduces gout flare inflammation. Avoid in patients with severe renal impairment (Cr Cl <30 m L/min) or peptic ulcer disease. Probenecid can increase serum levels of penicillins, cephalosporins, and NSAIDs. Colchicine toxicity risk increases with concurrent P-glycoprotein or CYP3A4 inhibitors (e.g., clarithromycin, cyclosporine). Monitor for myopathy and neuropathy. May cause a false-positive urinary glucose test.
Cholac (lactulose) is used for constipation and hepatic encephalopathy. Monitor for diarrhea and electrolyte imbalances. In hepatic encephalopathy, titrate dose to achieve 2-3 soft stools per day. Syrup can be mixed with fruit juice or water to improve palatability. Onset of action is 24-48 hours for constipation; for encephalopathy, effects may take several days.
Take with food or milk to reduce gastrointestinal upset.,Drink at least 2-3 liters of fluid daily to prevent kidney stones.,Avoid alcohol and high-purine foods (organ meats, shellfish) during therapy.,Report signs of toxicity: muscle weakness, numbness, tingling, severe diarrhea, or vomiting.,Do not take with macrolide antibiotics or antifungal medications without consulting your doctor.,Store at room temperature away from moisture and heat.
Take exactly as prescribed. Do not change dose without consulting your doctor.,For constipation, effects may take up to 48 hours. Do not use other laxatives unless advised.,For liver disease, it helps reduce ammonia levels. Aim for 2-3 soft bowel movements daily.,May cause gas, bloating, or stomach cramps, which usually decrease over time.,Contact doctor if you have severe diarrhea, vomiting, or signs of dehydration.,Store at room temperature, away from heat and direct light.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about COLBENEMID vs CHOLAC, answered by our medical review team.
COLBENEMID is a Antigout Agent Combination that works by Colchicine inhibits microtubule polymerization, reducing neutrophil chemotaxis and inflammation. Probenecid inhibits renal tubular reabsorption of uric acid, increasing uric acid excretion.. CHOLAC is a Laxative that works by Lactulose is a synthetic disaccharide that is not absorbed in the small intestine. It is metabolized by colonic bacteria to short-chain fatty acids, primarily lactic acid and acetic acid, which lower the colonic p H. This acidification traps ammonia (NH3) as ammonium (NH4+) in the gut lumen, reducing serum ammonia levels. Additionally, the osmotic effect of lactulose draws water into the colon, producing a laxative effect.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between COLBENEMID and CHOLAC depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of COLBENEMID is: Adults: 1 tablet (probenecid 500 mg / colchicine 0.5 mg) orally once daily for first week, then twice daily thereafter. May increase to 3-4 tablets daily in divided doses if needed.. The standard adult dose of CHOLAC is: 15-30 m L (10-20 g lactulose) orally once daily, titrated to produce 2-3 soft stools per day; maximum dose 60 m L/day. For hepatic encephalopathy: 30-45 m L (20-30 g) orally 3-4 times daily, titrated to 2-3 soft stools per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between COLBENEMID and CHOLAC in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. COLBENEMID is classified as Category C. Colbenemid is a combination of colchicine and probenecid. Colchicine is associated with increased risk of fetal harm when administered during pregnancy, including chromosomal abnor. CHOLAC is classified as Category C. Lactulose is not absorbed systemically; no teratogenic effects reported in animal studies or human case reports. FDA Pregnancy Category B. Trimester-specific risks: no known fetal . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.